Lash & Brow Growth Serums
Everyday exposureBeauty & personal careAlso called · 9 names▾▴
lash growth serum, eyelash growth serum, eyebrow growth serum, brow serum pregnancy, lash serum pregnancy, lash serum breastfeeding, prostaglandin lash serum, peptide lash serum, biotin eyelash serum
Treatments
General information · effects depend on amount, timing, and how it is used. About these sources
Research strength: 2 / 5
The LATISSE label states that there are no adequate, controlled pregnancy studies for prescription bimatoprost; it limits use to situations where potential benefit justifies fetal risk. The European Commission's SCCS did not endorse cosmetic lash or brow use of three named analogues, isopropyl cloprostenate, MDN, and DDDE, because acceptable reproductive and developmental data were lacking. NHS guidance frames bimatoprost eye drops differently when they treat glaucoma or high eye pressure, where continued treatment can be important. These findings are ingredient- and use-specific; they do not establish pregnancy outcomes for peptide, biotin, or other formulas. Evidence for the full lash and brow serum category is insufficient. Ask your provider about your situation.
Last reviewed: 2026-10-18
Sources
- DailyMed: LATISSE (bimatoprost ophthalmic solution 0.03%) labelDrug company label
- European Commission SCCS: Opinion on prostaglandin analogues used in cosmetic products, SCCS/1680/25EU agency
- NHS: Pregnancy, breastfeeding and fertility while using bimatoprostUK government
Research strength: 2 / 5
The LATISSE label states that there are no adequate, controlled pregnancy studies for prescription bimatoprost; it limits use to situations where potential benefit justifies fetal risk. The European Commission's SCCS did not endorse cosmetic lash or brow use of three named analogues, isopropyl cloprostenate, MDN, and DDDE, because acceptable reproductive and developmental data were lacking. NHS guidance frames bimatoprost eye drops differently when they treat glaucoma or high eye pressure, where continued treatment can be important. These findings are ingredient- and use-specific; they do not establish pregnancy outcomes for peptide, biotin, or other formulas. Evidence for the full lash and brow serum category is insufficient. Ask your provider about your situation.
Last reviewed: 2026-10-18
Sources
- DailyMed: LATISSE (bimatoprost ophthalmic solution 0.03%) labelDrug company label
- European Commission SCCS: Opinion on prostaglandin analogues used in cosmetic products, SCCS/1680/25EU agency
- NHS: Pregnancy, breastfeeding and fertility while using bimatoprostUK government
Research strength: 2 / 5
The LATISSE label states that there are no adequate, controlled pregnancy studies for prescription bimatoprost; it limits use to situations where potential benefit justifies fetal risk. The European Commission's SCCS did not endorse cosmetic lash or brow use of three named analogues, isopropyl cloprostenate, MDN, and DDDE, because acceptable reproductive and developmental data were lacking. NHS guidance frames bimatoprost eye drops differently when they treat glaucoma or high eye pressure, where continued treatment can be important. These findings are ingredient- and use-specific; they do not establish pregnancy outcomes for peptide, biotin, or other formulas. Evidence for the full lash and brow serum category is insufficient. Ask your provider about your situation.
Last reviewed: 2026-10-18
Sources
- DailyMed: LATISSE (bimatoprost ophthalmic solution 0.03%) labelDrug company label
- European Commission SCCS: Opinion on prostaglandin analogues used in cosmetic products, SCCS/1680/25EU agency
- NHS: Pregnancy, breastfeeding and fertility while using bimatoprostUK government
Lash & Brow Growth Serums — Breastfeeding
Research strength: 1 / 5
LactMed reports no information on bimatoprost use during breastfeeding. The LATISSE label says it is unknown whether topical eye use can produce detectable amounts in human milk. NHS guidance says bimatoprost eye drops may be used while breastfeeding for glaucoma or high eye pressure, but its page does not assess cosmetic lash-line products. The sources reviewed do not report studies of peptide or biotin lash serums during breastfeeding. Evidence for the broad serum category is insufficient. Ask your provider about your situation.
Last reviewed: 2026-10-18
Sources
- LactMed: BimatoprostUS government
- DailyMed: LATISSE (bimatoprost ophthalmic solution 0.03%) labelDrug company label
- NHS: Pregnancy, breastfeeding and fertility while using bimatoprostUK government
Pregnancy
Direct human pregnancy outcome studies for lash and brow serums were not identified. The LATISSE label states that there are no adequate, controlled studies in pregnant women and frames prescription use around whether potential benefit justifies potential fetal risk. In its final 2026 opinion, the European Commission's SCCS assessed three cosmetic analogues: isopropyl cloprostenate, methylamido-dihydro-noralfaprostal (MDN), and dechloro dihydroxy difluoro ethylcloprostenolamide (DDDE). The committee said its data did not allow it to support their use in lash and brow cosmetics because pharmacologic activity was strong and acceptable reproductive and developmental data were lacking. This conclusion is specific to those cosmetic ingredients and does not provide a pregnancy outcome rate or evaluate all serum formulas. The NHS page discusses bimatoprost eye drops for glaucoma or high eye pressure, where treatment may be important; it does not evaluate cosmetic lash-line use. The 2024 review and the Danish EPA report also do not provide pregnancy outcomes for peptide or biotin lash products.
Breastfeeding
LactMed's record, last revised December 15, 2024, reports no information on bimatoprost use during breastfeeding. The LATISSE label says it is unknown whether topical ocular use can produce detectable amounts in human milk. Neither source studies cosmetic prostaglandin-analogue serums or peptide and biotin formulas applied along the lash line.
Lash and brow serums are a product category, not one formula. LATISSE is prescription ophthalmic bimatoprost, a prostaglandin analogue used for eyelash hypotrichosis. Cosmetic products may contain other prostaglandin analogues, including isopropyl cloprostenate, MDN, or DDDE, or non-prostaglandin ingredients such as peptides, amino acids, vitamins, plant extracts, and biotin. A 2025 Danish EPA report and a 2026 survey of cosmetic products found both analogue-containing and non-prostaglandin formulas in their samples; these samples do not represent every brand or product. FDA says product classification depends on intended use and claims. A Health Canada alert reported undeclared bimatoprost in one lot of a product called Multi-Peptide Lash Serum; the alert is limited to that product lot.
What was tested
The 2025 Danish EPA report identified 58 unique lash or brow serum products from online shops; 14 contained prostaglandins or analogues, and the remaining 44 were reviewed further. Nineteen products containing selected peptides were purchased and analyzed by UPLC-MS2 for three peptides. This was a product and ingredient assessment, not a pregnancy or breastfeeding outcomes study, and it did not analyze every ingredient in every product. A 2026 qualitative study examined 79 cosmetic products promising longer or fuller eyelashes and found that about 30% of its sample contained a prostaglandin analogue; this was a product sample, not a market-wide estimate. The 2024 Baiyasi review concluded that formal evidence for non-prostaglandin ingredients in eyelash serum use was limited. A 2026 systematic review of topical bimatoprost included 45 studies and 7,106 participants, focused on periocular changes across glaucoma, ocular hypertension, and cosmetic use, not pregnancy or lactation outcomes.
Pregnancy and breastfeeding guidance for prescription bimatoprost eye treatment
- Source A says
- The LATISSE label reports no adequate, controlled pregnancy studies and frames pregnancy use around whether potential benefit justifies fetal risk. It also says human milk exposure after topical ocular use is unknown. (DailyMed: LATISSE (bimatoprost ophthalmic solution 0.03%) label)
- Source B says
- NHS guidance says bimatoprost treatment is important to continue during pregnancy or breastfeeding when it treats glaucoma or high eye pressure, with a clinician check. (NHS: Pregnancy, breastfeeding and fertility while using bimatoprost)
- Why they differ
- The NHS page addresses treatment of glaucoma or high eye pressure, where continued treatment may protect eye health. The LATISSE label covers prescription bimatoprost for eyelash hypotrichosis and gives a benefit-risk caution. Neither source evaluates cosmetic serums with other analogues or peptide and biotin formulas.
- What the evidence shows overall
- This is a difference in clinical framing for prescription eye treatment, not a study showing outcomes from cosmetic serum use. Evidence for the broad lash and brow serum category remains insufficient.
- FDA explains that intended use and marketing claims help determine whether a product is regulated as a cosmetic, a drug, or both; claims about hair growth can affect that classification. (FDA: Is It a Cosmetic, a Drug, or Both?)
- The SCCS opinion assessed three specific cosmetic analogues: isopropyl cloprostenate, MDN, and DDDE. Its conclusions do not cover every lash serum formula. (European Commission SCCS: Opinion on prostaglandin analogues used in cosmetic products, SCCS/1680/25)
- Health Canada's alert was limited to lot 20221230 of a product named Multi-Peptide Lash Serum and reported an undeclared bimatoprost ingredient; it is not a general finding about peptide serums. (Health Canada: Multi-Peptide Lash Serum alert)
General research, not specific to pregnancy.
The LATISSE label lists local eye and eyelid effects and postmarketing reports of periorbital changes for prescription bimatoprost. FDA and EMA records describe updates to bimatoprost product information. A 2026 systematic review reported higher relative risks for some periocular changes compared with latanoprost, but evidence certainty was low or very low and the review covered several uses. These findings do not establish the same effects or rates for every cosmetic serum.
- The LATISSE label lists iris pigmentation that may be permanent, eyelid darkening, hair growth outside the treatment area, and postmarketing reports of periorbital fat atrophy with deepening of the eyelid sulcus and eyelid ptosis. It says the frequency of voluntary postmarketing reports cannot be reliably estimated. (DailyMed: LATISSE (bimatoprost ophthalmic solution 0.03%) label)
- FDA's safety-labeling database records a 2021 LATISSE label update that includes periorbital fat atrophy and eyelid changes among postmarketing reports. EMA's PRAC stated that a causal relationship between bimatoprost and prostaglandin-associated periorbitopathy was established and recommended a product-information change. These findings concern bimatoprost-containing medicines, not every cosmetic serum ingredient. (FDA CDER: Safety-related labeling changes for LATISSE (NDA 022369), SUPPL-14, EMA PRAC: Scientific conclusions on bimatoprost and prostaglandin analogue periorbitopathy)
- A 2026 systematic review and meta-analysis included 45 studies with 7,106 participants. In five comparative studies, it reported a risk ratio of 2.92 for upper-eyelid sulcus deepening and 3.10 for periorbital fat loss with bimatoprost compared with latanoprost. The review rated certainty low for sulcus deepening and very low for fat loss, and included glaucoma, ocular hypertension, and cosmetic use. (Sheather et al. 2026: Periorbital Fat Atrophy With Topical Bimatoprost, systematic review and meta-analysis)
Experiences from moms and non-medical voices. Not medical evidence.
- DailyMed: LATISSE (bimatoprost ophthalmic solution 0.03%) labelDrug company labelTertiary
- LactMed: BimatoprostUS governmentSecondaryPage dated 2024-12-15Independent check
- European Commission SCCS: Opinion on prostaglandin analogues used in cosmetic products, SCCS/1680/25EU agencySecondaryPage dated 2026-02-10Independent check
- NHS: Pregnancy, breastfeeding and fertility while using bimatoprostUK governmentSecondaryPage dated 2024-09-02Independent check
- FDA: Is It a Cosmetic, a Drug, or Both?US governmentSecondary
- Danish Environmental Protection Agency: Survey and risk assessment of eyelash and eyebrow serumsPrimary
- Baiyasi et al. 2024: Eyelash serums, a comprehensive reviewUS governmentPrimary
- Couteau and Coiffard 2026: Prostaglandin analogues in cosmetic products formulated for eyelash lengtheningUS governmentPrimary
- Sheather et al. 2026: Periorbital Fat Atrophy With Topical Bimatoprost, systematic review and meta-analysisUS governmentPrimaryPage dated 2026-09-28
- Health Canada: Multi-Peptide Lash Serum undeclared ingredient alertGovernment regulatorSecondaryPage dated 2023-08-21
- FDA CDER: Safety-related labeling changes for LATISSE (NDA 022369), SUPPL-14Drug company labelSecondaryPage dated 2021-08-26Independent check
- EMA PRAC: Scientific conclusions on bimatoprost and prostaglandin analogue periorbitopathyEU agencySecondaryPage dated 2021-11-11Independent checkEuropean guidance
Last reviewed 2026-10-18
Independent check 2026-10-18
Not yet clinician-reviewed
Ask your provider about your situation.